Vasculitis & polymyalgia rheumatica
Identification of Covariates Modulating B‐Cell Repopulation Kinetics in Subjects Receiving Rituximab Treatment
Authors' conclusion
Co-medication with corticosteroids or azathioprine prolongs B-cell recovery, which may increase therapeutic effects but also the rate of adverse events.
Study context
- Population
- Subjects receiving RTX for autoimmune diseases2,017 RTX courses
- Participants
- 839 subjects
- Exposure
- Patient-specific factors and co-immunosuppression as covariates of B-cell repopulation after RTX
- Outcome
- Time to B-cell repopulation (≥5/μl)
Methodological detailssingle-centre, observational, multivariate time-to-event analysis, logistic regression
- Single-centre
- Observational
- Multivariate time-to-event analysis
- Logistic regression
Main finding
As reported in the abstract
B-cell repopulation (covariates associated with impaired repopulation and reconstitution)
- Age over 60 years, HR for repopulation (P = 0.008)
- 0.71
- Impaired kidney function, HR (P = 0.001)
- 0.72
- AAV, HR (P < 0.001)
- 0.61
- Solid organ transplantation, HR (P < 0.001)
- 0.4
- Co-immunosuppression with GC, HR (P < 0.001)
- 0.64
- Co-immunosuppression with AZA, HR (P < 0.001)
- 0.49
Observational data: associations, not effects.
Secondary outcomes
Dose dependence of covariate effects
- GC effect dose dependent (P = 0.043)
- AZA effect dose dependent (P = 0.025)
Original publication
Identification of Covariates Modulating B‐Cell Repopulation Kinetics in Subjects Receiving Rituximab Treatment. Arthritis Rheumatol. Published 7 September 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →